← All trials
NCT03432923
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2018
- Primary completion
- Apr 21, 2018
- Completion date
- Apr 21, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johnson and JohnsonLead sponsor
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.